Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXD101 + Nivolumab in MSS Colorectal Cancer
NCT03993626Phase 2
Key facts
- Status
- Unknown
- Start
- May 2018
- Primary completion
- Dec 2019
- Countries
- 1
- Sponsor
- Celleron Therapeutics
- Modality
- Small Molecules
- Drugs
- zabadinostat
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label, single-arm trial of zabadinostat in colorectal cancer (CRC), sponsored by Celleron Therapeutics. Primary endpoint: Immune Disease Control Rate at 6 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
CXD101 + Nivolumab
Combination of CXD101 (Zabadinostat) and Nivolumab
03
Who it enrols
Patients with metastatic, previously-treated, Microsatellite-Stable (MSS) Colorectal Carcinoma who have progressed on oxaliplatin and irinotecan.
04
Endpoints
Primary
Immune Disease Control Rate
Secondary
Immune-related Progression-Free Survival
Best Objective Response Rate
Overall Survival
Number of Participants With Abnormal Laboratory Values and/or Adverse Events
Beyond the preview
Go deeper on NCT03993626.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993626.